Abbott GMP Warning Letter Accelerates Monitoring Systems Validation Work
This article was originally published in The Gray Sheet
Executive Summary
Abbott is accelerating enhancements to its monitoring systems validation program at the company's Austin, Texas facility following receipt of an FDA warning letter related to production of hospital products, including I.V. drug solutions